

Organocatalysis

International Edition: DOI: 10.1002/anie.201507796
German Edition: DOI: 10.1002/ange.201507796Chemoselective Switch in the Asymmetric Organocatalysis of 5*H*-Oxazol-4-ones and *N*-Itaconimides: Addition–Protonation or [4 + 2] CycloadditionBo Zhu⁺, Richmond Lee⁺, Jiangtao Li⁺, Xinyi Ye, San-Ni Hong, Shuai Qiu, Michelle L. Coote,^{*} and Zhiyong Jiang^{*}

Abstract: We report a synthetic strategy for a chemoselective switch and a diastereo-divergent approach for the asymmetric reaction of 5*H*-oxazol-4-ones and *N*-itaconimides catalyzed by *L*-tert-leucine-derived tertiary amine–urea compounds. The reaction was modulated to harness either tandem conjugate addition–protonation or [4+2] cycloaddition as major product with excellent enantio- and diastereoselectivities. Subjecting the enantio-enriched cycloaddition products to a basic silica gel reagent yields the diastereomer vis-à-vis the product directly obtained under conditions for addition–protonation, thus opening a diastereo-divergent route for creating 1,3-tertiary-hetero-quaternary stereocenters. Quantum chemical studies further provide stereochemical analysis for the [4+2] process and a plausible mechanism for this chemoselective switch is proposed.

Reactions featuring switchable chemoselectivity enable the same set of starting substrates to generate distinct products under controlled experimental conditions, effectively expanding molecular diversity and scope. As a result, reaction strategies allowing chemodivergence have been acknowledged as one of the most promising developments in organic and medicinal chemistry.^[1,2] However, such examples are few,^[2] highlighting difficulties in precisely tuning reaction conditions for desired chemoselectivity.

As α -alkyl- α -hydroxy carboxylic acid derivatives are key chiral structural motifs in biologically relevant molecules,^[3] interest in asymmetric reactions of 5*H*-oxazol-4-ones has grown significantly in the past decade.^[4] The challenge remains for the asymmetric tandem conjugate addition–

protonation^[5] of 5*H*-oxazol-4-ones providing molecules bearing 1,3-tertiary-hetero-quaternary stereocenters.^[3a,b] And only recently one such example was reported,^[4m] probably owing to difficulties in the stereo-control of protonation process. 5*H*-Oxazol-4-one possesses three reactive sites: C2, C4, and C5, but all literature surveyed to date focused on C–C bond formation at C5. We could theoretically exploit the electrophilic C2 site and deprotonated the C5 enolate, similar to 2-azadienes,^[6] to perform [4+2] cycloaddition with suitable dienophiles, thus making a polycyclic nitrogen heterocycle.^[7]

This work endeavours to identify reaction conditions that facilitate chemoselective switching in the asymmetric reaction between 5*H*-oxazol-4-ones and *N*-itaconimides catalyzed by *L*-tert-leucine-derived tertiary amine–urea compounds (Figure 1). The judicious choice of solvent, temperature, and




Figure 1. Organocatalytic asymmetric reaction between 5*H*-oxazol-4-ones and *N*-itaconimides. Tandem conjugate addition–protonation = T-CAP.

catalyst should ultimately yield highly enantio-enriched [4+2] products after cycloaddition or tandem conjugate addition–protonation. As a corollary, we employed a basic silica gel reagent for the work-up of cycloaddition products to give corresponding diastereoisomers, enabling diastereo-divergent creation of 1,3-tertiary-hetero-quaternary stereocenters. Enantio-divergence could be realized simply by using the enantiomer of the organocatalyst.

We initiated our study by testing the feasibility of tandem conjugate addition–protonation of 5*H*-oxazol-4-one **1a**, and

[*] B. Zhu,^[+] J. Li,^[+] S.-N. Hong, S. Qiu, Prof. Dr. Z. Jiang
Key Laboratory of Natural Medicine and
Immuno-Engineering of Henan Province, Henan University
Jinming Campus, Kaifeng, Henan, 475004 (P.R. China)
E-mail: chmjzy@henu.edu.cn

R. Lee,^[+] Prof. Dr. M. L. Coote
ARC Centre of Excellence for Electromaterials Science
Research School of Chemistry, Australian National University
Canberra ACT 2601 (Australia)
E-mail: michelle.coote@anu.edu.au

X. Ye
Division of Chemistry and Biological Chemistry
Nanyang Technological University
21 Nanyang Link, 637371, Singapore (Singapore)

[+] These authors contributed equally to this work.

Supporting information for this article is available on the WWW
under <http://dx.doi.org/10.1002/anie.201507796>.

Table 1: Optimization of reaction conditions.^[a]

Entry	Cat.	Solv./T [°C]	t [h]	3a:4a ^[b]	Yield [%] ^[c]	3a ee [%] ^[d]	d.r. ^[b]	4a Yield [%] ^[c]	4a ee [%] ^[d]
1	I	DCM/25	60	>99:1	82	82	3:1	N.A.	N.A.
2	II	DCM/25	12	>99:1	87	93	5:1	N.A.	N.A.
3	III	DCM/25	12	>99:1	90	95	6:1	N.A.	N.A.
4	III	DCM/5	36	>99:1	88	96	7:1	N.A.	N.A.
5 ^[e]	III	DCM/5	72	>99:1	87	96	9:1	N.A.	N.A.
6	III	Et ₂ O/25	2	1:2.4	24	98	3:1	56	59
7	IV	Et ₂ O/25	4	1:3	15	96	1:1	56	71
8	IV	Et ₂ O/5	16	1:3	20	94	1:1	65	68
9	IV	C ₆ HF ₅ /5	12	2:1	65	98/93	1:1	28	83
10 ^[f]	IV	C ₆ HF ₅ /−5	16	1:5	16	99/99	1:1	68	92

[a] Reaction conditions: **1a** (0.05 mmol), **2a** (0.075 mmol), solvent (0.5 mL). [b] The ratio of **3a**:**4a** and d.r. were determined by crude ¹H NMR. The dr of **4a** > 19:1. [c] The yield was isolated by flash column. [d] The ee was determined by HPLC. [e] 2.5 mL solvent was used. [f] 5 mol% of catalyst **IV**.

N-phenyl itaconimide **2a** as an acceptor (Table 1).^[8] The class of electrophile chosen, *N*-itaconimides, which contains an activated exocyclic alkene, have been used previously as the electrophile in catalytic asymmetric protonation to assemble chiral succinimides with biological targets.^[8] However, employing them in tandem conjugate addition–protonation to construct two nonadjacent stereocenters is a first. *L*-tert-Leucine-derived tertiary amine–thiourea bifunctional catalyst **I**, the efficacy of which has been demonstrated by us and others,^[9] was first put to the test. The addition–protonation adduct **3a** was obtained in 82 % yield with 82 % ee and 3:1 d.r. within 60 hours (Table 1, entry 1). Both enantio- and diastereoselectivity were improved by using another variant, catalyst **II** (93 % ee, 5:1 d.r., Table 1, entry 2). Even better stereoselectivity was seen with 3,5-dimethoxyphenyl catalyst **III** in which **3a** was obtained with 95 % ee and 6:1 d.r. (Table 1, entry 3). The reaction performed at 5 °C produced **3a** in 96 % ee and 7:1 d.r. (Table 1, entry 4); and the d.r. value was further increased to 9:1 when the concentration was diluted five times (Table 1, entry 5).

By enlisting the reaction conditions in entry 6 of Table 1, we were intrigued to be able to isolate the [4+2] cycloaddition adduct **4a** as the major product.^[10] This discovery prompted us to screen reaction conditions, so as to synthesize **4a** with improved yield and stereoselectivity. It was found that catalyst **IV**, an analog of catalyst **III**, is a more suitable catalyst candidate to produce **4a** (Table 1, entry 7). Unfortunately for Et₂O at lower temperature the enantioselectivity stayed the same (5 °C, Table 1, entry 8), so other low polarity solvents were screened.^[10] Pentafluorobenzene (C₆HF₅) as solvent at 5 °C gave 28 % yield of **4a** and higher ee at 83 % (Table 1, entry 9). Performing the reaction in C₆HF₅ at −5 °C with lower catalyst loading of 5.0 mol% **IV** afforded **4a** in 68 % yield with 92 % ee (Table 1, entry 10).

With the optimal conditions established earlier for tandem conjugate addition–protonation^[10] (10 mol % of catalyst **III**, CH₂Cl₂, 5 °C), substrate screening of various *N*-substituted *N*-itaconimides **2** and 5*H*-oxazol-4-ones **1** bearing 3-methylphenyl on C2 position and different substituents on C5 position was carried out (Table 2). All screened reactions proceeded smoothly and completed within 24–96 hours, giving adducts **3b–r** in 80–96 % yield with 91–99 % ee and 7:1 to 15:1 d.r. Employing 10 mol % of *ent*-**III** as catalyst gave *ent*-**3b** in 92 % yield with 97 % ee and 10:1 d.r. after 72 hours (footnote c). The addition–protonation process was also effective with 5*H*-oxazol-4-ones bearing 3-bromophenyl on C2 position, affording adducts **3s–u** in

Table 2: Tandem conjugate addition–protonation of **1** and **2** catalyzed by **III**.^[a]

Entry	Ar	R'	Yield [%]	d.r.	ee [%]
3b	3-MePh	Ph	72 h, 95%	13:1	97%
3c	4-CF ₃ Ph	Ph	72 h, 83%	13:1	97%
3d	4-FPh	Ph	60 h, 88%	13:1	97%
3e	4-BrPh	Ph	72 h, 85%	12:1	97%
3f	4-MePh	Ph	72 h, 88%	15:1	96%
3g	4-MeOPh	Ph	72 h, 95%	13:1	96%
3h	4-ClPh	Ph	72 h, 88%	15:1	97%
3i	3-ClPh	Ph	60 h, 83%	12:1	98%
3j	3-BrPh	Ph	48 h, 82%	12:1	97%
3k	3-MePh	Ph	63 h, 90%	12:1	96%
3l	3,5-Me ₂ Ph	Ph	72 h, 84%	13:1	91%
3m	2-naphthyl	Ph	72 h, 84%	13:1	96%
3n	3-BrPh	Bn	96 h, 84%	13:1	99%
3o	3-BrPh	Bn	96 h, 82%	7:1	98%
3p	3-BrPh	Bn	24 h, 96%	12:1	99%
3q	3-BrPh	Bn	96 h, 80%	8:1	99%
3r	3-BrPh	Bn	96 h, 80%	10:1	99%
ent-3b	3-BrPh	Ph	72 h, 92%	10:1	97%
3s	3-BrPh	Ph	16 h, 87%	9:1	98%
3t	3-BrPh	Ph	21 h, 82%	13:1	98%
3u	3-BrPh	Ph	16 h, 85%	8:1	99%

[a] Reaction conditions: **1** (0.2 mmol), **2** (0.3 mmol), **III** (0.02 mmol), CH₂Cl₂ (10 mL), 5 °C. The yield was isolated by flash column. The ee was determined by HPLC. The dr was determined by crude ¹H NMR spectroscopy. [b] 10 °C and 4 mL CH₂Cl₂ was used. [c] 10 mol % of *ent*-**III** was used.

82–87 % yield with 98–99 % ee and 8:1 to 13:1 d.r. The stereochemistry of the tandem conjugate addition–protonation products were assigned based on the structure of **3h**, as solved by single-crystal X-ray diffraction.^[12]

Table 3: Reaction of **1** and **2** catalyzed by **IV**.

1) -5 °C in C ₆ H ₅ F ₅ ^[a]	
4a: R' = Ph 18 h, 72% yield, 93% ee 4b: R' = 4-FPh 20 h, 74% yield, 90% ee 4c: R' = Me 36 h, 68% yield, 91% ee 4d: R' = 4-BrPhCH ₂ 60 h, 87% yield, 94% ee	4e: Ar = 4-BrPh, 18 h 87% yield, 93% ee 4f: Ar = 4-ClPh, 18 h 75% yield, 94% ee 4g: Ar = 3,5-Me ₂ Ph, 24 h 67% yield, 94% ee
4h: R = Me, R' = Ph 16 h, 80% yield, 94% ee ent-4h: R = Me, R' = Ph 20 h, 79% yield, 96% ee ^[b] 4i: R = Me, R' = 4-ClPh 18 h, 92% yield, 96% ee 4j: R = Me, R' = 3-ClPh 18 h, 86% yield, 95% ee	4k: R = Me, R' = 4-MePh 18 h, 86% yield, 97% ee 4l: R = Me, R' = 4-MeOPh 18 h, 84% yield, 96% ee 4m: R = Me, R' = 4-BrPhCH ₂ 20 h, 88% yield, 97% ee 4n: R = Me, R' = 4-MeOPhCH ₂ 20 h, 92% yield, 95% ee
4r: 18 h 85% yield, 99% ee 4s: 36 h 68% yield, 94% ee 4t: 24 h 72% yield, 99% ee 4u: 20 h 74% yield, 98% ee	
2) 5 °C in CH ₂ Cl ₂ ^[c] (Ar = 3-MePh)	
3b: 48 h, 89% yield 5:1 d.r., 96% ee 3i: 48 h, 91% yield 8:1 d.r., 96% ee 3j: 48 h, 93% yield 8:1 d.r., 96% ee	

[a] Reaction conditions: **1** (0.2 mmol), **2** (0.4 mmol), **IV** (0.01 mmol), C₆H₅F₅ (4.0 mL), -5 °C. The yield was isolated by flash column. The *ee* was determined by HPLC. The dr was determined by crude ¹H NMR spectroscopy. All dr values > 19:1. [b] *ent-IV* was catalyst. [c] Reaction conditions: **1** (0.2 mmol), **2** (0.3 mmol), **IV** (0.02 mmol), CH₂Cl₂ (10 mL), 5 °C. The yield was isolated by flash column. The *ee* was determined by HPLC. The dr was determined by crude ¹H NMR spectroscopy.

Next we turned our attention to generating other derivatives of **4a** (Table 3 part 1). The reactions were performed in the presence of 5 mol % of **IV** in C₆H₅F₅ as solvent at -5 °C, and a series of products **4a–4u** were obtained in 68–92% yield with 90–99% *ee*. These results show that the reaction is applicable to a wide range of 5*H*-oxazol-4-ones containing different substituents on C2 and C5 positions and *N*-phenyl, benzyl, and alkyl-substituted itaconimides. The absolute configuration of cycloaddition products were assigned based on X-ray crystallographic analysis of **4h**.^[11] We also carried out several reactions by employing enantiomeric *ent-IV* catalyst in CH₂Cl₂ as solvent at 5 °C (Table 3 part 2), and the corresponding tandem conjugate addition–protonation products **3b** and **3i–j** were obtained with similarly high *ee* values but slightly depressed dr values (dr = diastereomeric ratio) as compared to **III** as the catalyst (Table 2). These results indicate that a strategy for a chemoselectivity switch could be realized by conveniently tuning solvent and temperature.

In order to guide our understanding of the mechanism and observed stereochemical outcomes, dispersion-corrected density functional theory (DFT) calculations at the M06-2X(D3)/def2-TZVP/SMD//B3LYP/6–31G(d,p)/SMD level of theory

were carried out to model the reactions of substrates **1a**, **2a**, and catalyst **IV**.^[10] First, the electrophile **2a** could approach the bound zwitterionic catalyst–nucleophile complex **IV-1a** in either an eclipsed or staggered fashion. The transition state (TS) for the eclipsed approach is more stable than the staggered one by as much as 2.7 kcal mol⁻¹ because of secondary π – π^* orbital interactions^[9c] and based on this eclipsed approach, there are four possible stereo-outcomes (see Figures S1 and S2 in the Supporting Information). Comparison of all of the relative Gibbs free activation energies of the TS of these four stereo-outcomes in the first Michael addition (Figure 2) reveal that the TS is most stable




Figure 2. TS for the Michael addition process. Values are Gibbs free energy and enthalpy (kcal mol⁻¹) of dichloromethane (DCM) optimized transition-state electronic structures relative to free starting materials **1a**, **2a**, and **IV**.

when the substrates are fused in a *Re,Si* fashion (**TS1-R,S[IV]**, $\Delta G^\ddagger = +15.9$ kcal mol⁻¹). TS structures optimized with *Si,Re-Re,Re-* or *Si,Si-facing* substrates (**TS1-S,R[IV]**, **TS1-R,R[IV]** and **TS1-S,S[IV]** respectively) were calculated to be less stable ($\Delta G^\ddagger = +18.0$ to $+20.0$ kcal mol⁻¹) and thus likely to be less competitive kinetically.

The distortion/interaction model was employed to further analyze the reactivity of the first enantio-discriminating TSs,^[11] with **TS1-R,S[IV]** revealing the strongest interaction energy and consequently lowest activation energy (Figure 2). The subsequent steps following the *Re,Si* pathway were fully modeled to provide a plausible understanding for the observed chemoselective switch. We propose in essence, the first isolable [4+2] cycloaddition product **4a** via *Re,Si* pathway ($\Delta G = -7.9$ kcal mol⁻¹) is not the most thermodynamically stable product formed. Instead, addition–protonation products **3a** and its diastereomer **3a'**, $\Delta G = -9.1$ kcal mol⁻¹ and -12.6 kcal mol⁻¹, respectively, are more stable and could be transformed from **4a** with elevation in reaction temperature (see the Supporting Information for full explanation).

Finally, the synthetic utility of this work is demonstrated here. Treatment of cycloaddition product **4h** with 0.5 equiv of LiOH in CH₂Cl₂ at -10 °C led to 1:1 ratio of **3s** and its diastereoisomer **3s'** without compromising *ee* value.^[10] Differ-

ent inorganic bases were also examined and NaOH was found to give **3s'** with d.r. of 2:1. No reaction was observed when weaker bases, such as NaHCO₃ and Na₂CO₃, were used. Interestingly, a more efficient reagent is obtained by treating silica gel with base (NaOH/silica gel = 40 mg/10 g), which promoted this transformation with satisfactory diastereoselectivity. In the presence of basic silica gel reagent in C₆HF₅ at 5 °C, a series of **3'** were obtained from the corresponding cycloaddition products (**4s–u**, **4h** and **4p–q**) in 68–93 % yield with 12:1 to >19:1 d.r. and high *ee* (Scheme 1.1). Further-

method for the asymmetric creation of two nonadjacent stereocenters.^[5a,b]

Hydroxylation of **3b** was then performed with 5.0 equiv of NaHCO₃ in THF at 25 °C (Scheme 1 part 2). Amide **5** with a benzoyl-protected α -tertiary alcohol was obtained in 68 % yield after 26 hours without compromising *ee* value and d.r. In the same light, the enantiomer and a pair of enantiomeric diastereoisomers of **5** could be conveniently achieved from *ent-3b* (Table 2), **3s'** and *ent-3s'* (Scheme 1 part 1) through this methodology. Reduction of **4h** with a borane dimethyl sulfide complex afforded a highly interesting spiro-piperidine-pyrrolidine derivative **6**, which is important in pharmaceuticals (Scheme 1 part 3).^[15]

In summary, we have successfully developed expedient and practical routes for realizing a novel asymmetric and chemoselective switch strategy between 5*H*-oxazol-4-ones and *N*-itaconimides. The *L*-tert-leucine-derived tertiary amine-urea catalyst under established protocols (reaction media and temperature) worked efficiently to selectively produce tandem conjugate addition–protonation and [4+2] cycloaddition products with excellent enantio- and diastereoselectivities. Furthermore, the diastereoselectivity of tandem conjugate addition–protonation could be improved by tuning the electronic properties of catalyst. This study is also the first synthetic demonstration to take advantage of electrophilic C2 atom of 5*H*-oxazol-4-ones in asymmetric catalysis. For the diastereo-divergent route we devised a novel basic silica gel reagent promote the conversion of the cycloaddition adducts to the corresponding diastereoisomers of addition–protonation adducts with good results, thus furnishing the enantio- and diastereo-divergent creation of 1,3-tertiary-hetero-quaternary stereocenters. Future investigations, involving kinetic studies and computations will be detailed to fully understand the mechanistic underpinnings of the chemoselectivity switch.

Acknowledgements


Z.J. is grateful for the grants from NSFC (grant number 21072044), NCET-11-0938 and the Program for Innovative Research Team from the University of Henan Province (14IRTSTHN006). M.L.C. gratefully acknowledges generous allocations of supercomputing time on the National Facility of the National Computational Infrastructure, and financial support from the Australian Research Council. R.L. also acknowledges Dr. Xiaohe Miao (KAUST) for supplementary computing time.

Keywords: chemoselectivity · chirality · density functional calculations · organocatalysis · synthetic methods


How to cite: *Angew. Chem. Int. Ed.* **2016**, 55, 1299–1303
Angew. Chem. **2016**, 128, 1321–1325

- [1] For selected reviews, see: a) S. L. Schreiber, *Science* **2000**, 287, 1964; b) R. A. Shenvi, D. P. O'Malley, P. S. Baran, *Acc. Chem. Res.* **2009**, 42, 530; For selected examples, see: c) R. Lerebours, C. Wolf, *J. Am. Chem. Soc.* **2006**, 128, 13052; d) B. Alcaide, P.


1) The synthesis of **3'** as the diastereoisomers of **3**^[a]



2) Hydrolysis of TCAP adducts



3) Reduction of cycloaddition products



Scheme 1. Synthetic routes used in this work. [a] Reaction on a 0.2 mmol scale. 4.0 g of basic silica gel (NaOH/silica gel = 40 mg/10 g) was used. For **P1**: yield of one step; for **P2**: yield of two steps. [b] Step 1 was performed for 36 hours. [c] From *ent-4h*. Yield was isolated by flash column. The *ee* was determined by HPLC. The dr was determined by crude ¹H NMR spectroscopy.

more, a tandem one-pot strategy through combining [4+2] cycloaddition and transformation by directly employing **1** and **2** as starting substrates was explored. Various **3'** were achieved in satisfactory yields with a slightly lower *ee* values and dr values (70–90 % yield of two steps, 83–96 % *ee* and 5:1 to 15:1 d.r.). The absolute configuration of **3'** products were confirmed based on single-crystal X-ray crystallographic analysis of **3s'**.^[13] To the best of our knowledge, this is one of the few examples reported to date of a diastereo-divergent^[5a,b,14]

- Almendros, T. M. del Campo, *Chem. Eur. J.* **2008**, *14*, 7756; e) H. Clavier, A. Correa, E. C. Escudero-Adán, J. Benet-Buchholz, L. Cavallo, S. P. Nolan, *Chem. Eur. J.* **2009**, *15*, 10244; f) S. Kirchberg, R. Fröhlich, A. Studer, *Angew. Chem. Int. Ed.* **2009**, *48*, 4235; *Angew. Chem.* **2009**, *121*, 4299; g) M. Szostak, M. Spain, B. Sautier, D. J. Procter, *Org. Lett.* **2014**, *16*, 5694; h) R. Shenje, C. W. Williams, K. M. Francois, S. France, *Org. Lett.* **2014**, *16*, 6468; i) M. Wang, X. Zhang, Y.-X. Zhuang, Y.-H. Xu, T.-P. Loh, *J. Am. Chem. Soc.* **2015**, *137*, 1341; j) X. Liu, X. Ye, F. Bures, H. Liu, Z. Jiang, *Angew. Chem. Int. Ed.* **2015**, *54*, 11443; *Angew. Chem.* **2015**, *127*, 11605.
- [2] a) X. Lu, Y. Liu, B. Sun, B. Cindric, L. Deng, *J. Am. Chem. Soc.* **2008**, *130*, 8134; b) F. Menard, M. Lautens, *Angew. Chem. Int. Ed.* **2008**, *47*, 2085; *Angew. Chem.* **2008**, *120*, 2115; c) B.-M. Fan, X.-J. Li, F.-Z. Peng, H.-B. Zhang, A. S. C. Chan, Z.-H. Shao, *Org. Lett.* **2010**, *12*, 304; d) L. Dell'Amico, G. Rassu, V. Zambrano, A. Sartori, C. Curti, L. Battistini, G. Pelosi, G. Casiraghi, F. Zanardi, *J. Am. Chem. Soc.* **2014**, *136*, 11107.
- [3] a) V. Helaine, J. Bolte, *Tetrahedron: Asymmetry* **1998**, *9*, 3855; b) P. Coutrot, S. Claudel, C. Didierjean, C. Grison, *Bioorg. Med. Chem. Lett.* **2006**, *16*, 417; c) L.-F. Zan, J.-C. Qin, Y.-M. Zhang, Y.-H. Yao, H.-Y. Bao, X. Li, *Chem. Pharm. Bull.* **2011**, *59*, 770; d) X. Wu, Y. Wang, X.-J. Huang, C.-L. Fan, G.-C. Wang, X.-Q. Zhang, Q.-W. Zhang, W.-C. Ye, *J. Asian Nat. Prod. Res.* **2011**, *13*, 728; e) Y.-B. Zhang, W. Li, X.-W. Yang, *Phytochemistry* **2012**, *81*, 109.
- [4] a) B. M. Trost, K. Dogra, M. Franzini, *J. Am. Chem. Soc.* **2004**, *126*, 1944; b) T. Misaki, G. Takimoto, T. Sugimura, *J. Am. Chem. Soc.* **2010**, *132*, 6286; c) T. Misaki, K. Kawano, T. Sugimura, *J. Am. Chem. Soc.* **2011**, *133*, 5695; d) H. Huang, K. Zhu, W. Wu, Z. Jin, J. Ye, *Chem. Commun.* **2012**, *48*, 461; e) B. M. Trost, K. Hirano, *Angew. Chem. Int. Ed.* **2012**, *51*, 6480; *Angew. Chem.* **2012**, *124*, 6586; f) D. Zhao, L. Wang, D. Yang, Y. Zhang, R. Wang, *Angew. Chem. Int. Ed.* **2012**, *51*, 7523; *Angew. Chem.* **2012**, *124*, 7641; g) B. Qiao, Y. An, Q. Liu, W. Yang, H. Liu, J. Shen, L. Yan, Z. Jiang, *Org. Lett.* **2013**, *15*, 2358; h) Z. Han, W. Yang, C.-H. Tan, Z. Jiang, *Adv. Synth. Catal.* **2013**, *355*, 1505; i) Q. Liu, B. Qiao, K. F. Chin, C.-H. Tan, Z. Jiang, *Adv. Synth. Catal.* **2014**, *356*, 3777; j) M. Xu, B. Qiao, S. Duan, H. Liu, Z. Jiang, *Tetrahedron* **2014**, *70*, 8696; k) E. Badiola, B. Fiser, E. Gómez-Bengoa, A. Mielgo, I. Olaizola, I. Urruzuno, J. M. García, J. M. Odriozola, J. Razkin, M. Oiarbide, C. Palomo, *J. Am. Chem. Soc.* **2014**, *136*, 17869; l) W. Chen, J. F. Hartwig, *J. Am. Chem. Soc.* **2014**, *136*, 377; m) T. Wang, Z. Yu, D. L. Hoon, K.-W. Huang, Y. Lan, Y. Lu, *Chem. Sci.* **2015**, *6*, 4912; n) T. Misaki, N.-R. Choi, A. Morita, T. Sugimura, *Tetrahedron Lett.* **2015**, *56*, 5063; o) S. Duan, S. Li, X. Ye, N.-N. Du, C.-H. Tan, Z. Jiang, *J. Org. Chem.* **2015**, *80*, 7770.
- [5] a) Y. Wang, X. Liu, L. Deng, *J. Am. Chem. Soc.* **2006**, *128*, 3928; b) B. Wang, F. Wu, Y. Wang, X. Liu, L. Deng, *J. Am. Chem. Soc.* **2007**, *129*, 768; c) X. Li, S. Luo, J.-P. Cheng, *Chem. Eur. J.* **2010**, *16*, 14290; d) L. M. Repka, J. Ni, S. E. Reisman, *J. Am. Chem. Soc.* **2010**, *132*, 14418; e) S.-W. Duan, J. An, J.-R. Chen, W.-J. Xiao, *Org. Lett.* **2011**, *13*, 2290; and reference [4m].
- [6] D. L. Boger, *Tetrahedron* **1983**, *39*, 2869.
- [7] a) F. Liu, D. J. Austin, *Org. Lett.* **2001**, *3*, 2273; b) F. Liu, E. F. Johnson, D. J. Austin, K. S. Anderson, *Bioorg. Med. Chem. Lett.* **2003**, *13*, 3587; c) H. Mizoguchi, H. Oguri, K. Tsuge, H. Oikawa, *Org. Lett.* **2009**, *11*, 3016; d) H. Oguri, H. Mizoguchi, H. Oikawa, A. Ishiyama, M. Iwatsuki, K. Otoguro, S. Omura, *Beilstein J. Org. Chem.* **2012**, *8*, 930.
- [8] a) D. Leow, S. Lin, S. K. Chittimalla, X. Fu, C.-H. Tan, *Angew. Chem. Int. Ed.* **2008**, *47*, 5641; *Angew. Chem.* **2008**, *120*, 5723; b) S. Lin, D. Leow, K.-W. Huang, C.-H. Tan, *Chem. Asian J.* **2009**, *4*, 1741.
- [9] For selected reviews, see: a) Z. Chai, G. Zhao, *Catal. Sci. Technol.* **2012**, *2*, 29; b) O. V. Serdyuk, C. M. Heckel, S. B. Tsogoeva, *Org. Biomol. Chem.* **2013**, *11*, 7051; c) X. Zhao, B. Zhu, Z. Jiang, *Synlett* **2015**, *26*, 2216; For our contributions, see: d) W. Zhang, D. Tan, R. Lee, G. Tong, W. Chen, B. Qi, K.-W. Huang, C.-H. Tan, Z. Jiang, *Angew. Chem. Int. Ed.* **2012**, *51*, 10069; *Angew. Chem.* **2012**, *124*, 10216; e) B. Zhu, W. Zhang, R. Lee, Z. Han, W. Yang, D. Tan, K.-W. Huang, Z. Jiang, *Angew. Chem. Int. Ed.* **2013**, *52*, 6666; *Angew. Chem.* **2013**, *125*, 6798; f) X. Bai, Z. Jing, Q. Liu, X. Ye, G. Zhang, X. Zhao, Z. Jiang, *J. Org. Chem.* **2015**, DOI: 10.1021/acs.joc.5b02286; and Ref. [4g].
- [10] See the Supporting Information for details. For DFT, all reported Gibbs free energies or enthalpies are relative to free starting materials **1a**, **2a** and **IV**.
- [11] For examples on distortion/interaction analyses for Diels–Alder, see: a) F. Liu, R. S. Paton, S. Kim, Y. Liang, K. N. Houk, *J. Am. Chem. Soc.* **2013**, *135*, 15642; b) R. S. Paton, S. Kim, A. G. Ross, S. J. Danishefsky, K. N. Houk, *Angew. Chem. Int. Ed.* **2011**, *50*, 10366; *Angew. Chem.* **2011**, *123*, 10550; c) W.-J. van Zeist, F. M. Bickelhaupt, *Org. Biomol. Chem.* **2010**, *8*, 3118.
- [12] No reaction was observed when **3a** was in the presence of [4+2] cycloaddition conditions.
- [13] CCDC 1054275 (**3h**), CCDC 1058188 (**4h**), CCDC 1058217 (**3s'**) and CCDC 1418364 (**6**) contain the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.
- [14] a) E. M. Carreira, L. Kvaerno, *Classics in Stereoselective Synthesis*, Wiley, Weinheim, **2009**; b) M. T. Oliveira, M. Luparia, D. Audisio, N. Maulide, *Angew. Chem. Int. Ed.* **2013**, *52*, 13149; *Angew. Chem.* **2013**, *125*, 13387; c) S. Krautwald, D. Sarlah, M. A. Schafroth, E. M. Carreira, *Science* **2013**, *340*, 1065; d) X. Li, M. Lu, Y. Dong, W. Wu, Q. Qian, J. Ye, D. Dixon, *Nat. Commun.* **2014**, *5*, 4479.
- [15] For selected examples, see: a) G. Mullen, J. Napier, M. Balestra, T. DeCory, G. Hale, J. Macor, R. Mack, J. Loch III, E. Wu, A. Kover, P. Verhoest, A. Sampognaro, E. Phillips, Y. Zhu, R. Murray, R. Griffith, J. Blosser, D. Gurley, A. Machulskis, J. Zongrone, A. Rosen, J. Gordon, *J. Med. Chem.* **2000**, *43*, 4045; b) R. R. Kumar, S. Perumal, P. Senthilkumar, P. Yogeewari, D. Sriram, *J. Med. Chem.* **2008**, *51*, 5731; c) K. Ishiuchi, T. Kubota, H. Ishiyama, S. Hayashi, T. Shibata, K. Mori, Y. Obara, N. Nakahata, J. Kobayashi, *Bioorg. Med. Chem.* **2011**, *19*, 749; d) S. Sivakumar, R. R. Kumar, M. A. Ali, T. S. Choon, *Eur. J. Med. Chem.* **2013**, *65*, 240; e) Y. Kia, H. Osman, R. S. Kumar, A. Basiri, V. Murugaiyah, *Bioorg. Med. Chem.* **2014**, *22*, 1318.

Received: August 20, 2015

Revised: October 21, 2015

Published online: December 9, 2015